Geron 2018 Annual Meeting of Stockholders
May 15, 2018 at 4:00 PM PDT
Webcast Presentation

Geron 2018 Annual Meeting of Stockholders
May 15, 2018 at 4:00 PM PDT

Corporate Profile

Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Imetelstat is currently being tested in two clinical trials: IMbark™, a Phase 2 trial in myelofibrosis (MF) and IMerge™, a Phase 2/3 trial in myelodysplastic syndromes (MDS). These clinical trials are being conducted by Janssen Biotech, Inc., under a collaboration and license agreement, in which Janssen were granted the exclusive rights to develop and commercialize imetelstat worldwide for all indications in oncology, including hematologic myeloid malignancies, and all other human therapeutic uses.

Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless, uncontrolled proliferation. Using Geron’s proprietary nucleic acid chemistry, imetelstat was designed as an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation. Early clinical data, including molecular responses in essential thrombocythemia (ET) and remissions, including reversal of bone marrow fibrosis in MF, suggest imetelstat may have disease-modifying activity by inhibiting the progenitor cells of the malignant clones for the underlying diseases.

Recent News

Date Title and Summary  
Toggle Summary Geron 2018 Annual Meeting of Stockholders to be Held on May 15
First Quarter 2018 Financial Results to be Announced on May 10 MENLO PARK, Calif. , April 17, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will hold its 2018 Annual Meeting of Stockholders, on Tuesday, May 15, 2018 , at 4:00 p.m. PDT . Geron’s stockholders are invited to attend the
Toggle Summary Geron to Present at the Needham Healthcare Conference
MENLO PARK, Calif. , March 21, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett , M.D., President and Chief Executive Officer, is scheduled to present at the 17th Annual Needham Healthcare Conference in New York at 4:00 p.m.
Toggle Summary Geron Corporation Reports Fourth Quarter and Annual 2017 Financial Results and Recent Events
Conference Call Scheduled for 8:30 a.m. ET on Monday, March 19 MENLO PARK, Calif. , March 16, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the fourth quarter and year ended December 31, 2017 and recent events.

Upcoming Events

More >>

Corporate Presentation


Stock Information

Copyright Nasdaq. Minimum 15 minutes delayed.

Contact Information

Anna Krassowska, Ph.D.